Skip to main
CPRX
CPRX logo

Catalyst Pharmaceuticals (CPRX) Stock Forecast & Price Target

Catalyst Pharmaceuticals (CPRX) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 53%
Buy 40%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Catalyst Pharmaceuticals Inc demonstrated a strong financial performance with total revenue of $141.8 million for the fourth quarter of 2024, reflecting a year-over-year increase of approximately 28.3%. The company is poised for continued growth, particularly through the expansion of FIRDAPSE into the cancer-associated LEMS market and the promising early momentum of AGAMREE's launch, which has shown significant penetration in the Duchenne Muscular Dystrophy (DMD) market. The ongoing demand for both FYCOMPA and new strategic opportunities in the orphan disease sector position Catalyst for sustained value creation and robust financial performance moving forward.

Bears say

The analysis indicates a negative outlook for Catalyst Pharmaceuticals Inc., primarily due to the potential inability to defend its drug portfolio, which poses a risk of losing market potential for its products. Additionally, concerns regarding access to capital and funding could hinder essential business functions, delaying the company’s path to profitability and cash flow generation. Furthermore, the risks associated with clinical efficacy, competition, and reliance on third-party manufacturing could impede the achievement of expected commercial revenue from its key products, FIRDAPSE, FYCOMPA, and AGAMREE.

Catalyst Pharmaceuticals (CPRX) has been analyzed by 15 analysts, with a consensus rating of Buy. 53% of analysts recommend a Strong Buy, 40% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Catalyst Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Catalyst Pharmaceuticals (CPRX) Forecast

Analysts have given Catalyst Pharmaceuticals (CPRX) a Buy based on their latest research and market trends.

According to 15 analysts, Catalyst Pharmaceuticals (CPRX) has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.08, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.08, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Catalyst Pharmaceuticals (CPRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.